Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
AstraZeneca has penned a deal with Harbour Biomed for its bispecific antibody HBM7022, which is intended to eliminate tumors in oncological patients.
The deal marks the first immuno-oncology program for Jazz Pharma. With it, they are trying to become a leading oncology company. Here’s more about their success.
Sunshine Biopharma, Inc announced this week that its novel-formulation mRNA molecules induce cancer cell death in cell cultures.
This week, two studies provided big insights into brain changes and specific genetic sites and risk factors for Alzheimer’s disease. For those and more, continue reading.
Global health officials are monitoring COVID-19 cases with an eye to identifying the emergence of new, potentially more deadly or more infectious variants. Read on for more details.
Pfizer is taking a deeper dive into infectious disease with the acquisition of North Carolina-based ReViral, a biotech focused on developing therapeutics that target respiratory syncytial virus (RSV).
An article in Nature explains that ten genes, upon severe mutation that alters genetic function, are linked to an increased risk of the development of schizophrenia.
The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy of Neurology’s annual meeting in Seattle.
Carver Biosciences is developing next-generation gene editing technology using Cas13. By editing RNA, this method makes it possible to target and then edit or destroy RNA from viruses like SARS-CoV-2.
Retro Biosciences announced on Twitter that it is launching with $180 million in funding. Not much is known about the company, except that it indicates it is focused on the “cellular drives of aging.”
A team of scientists from Mount Sinai was able to uncover specific tumor microenvironment (TME) regulators using a novel functional genomics technology known as Perturb-map.
The data demonstrated that the drug, when given to the patients for more than seven days, offered a protection rate of 100%.
PRESS RELEASES
• ASCO 2026: 2.5-Year Overall Survival Data • Jefferies Healthcare Conference: Partnering & Investor meetings • BIO International Convention: Panel Participation • MIB Agents Factor Osteosarcoma Conference: Data Presentation
The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia’s Authorised Prescriber Scheme, where no serious adverse events have been reported as of December 2025
Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDT
• MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM. • Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.
· Prof. Dr. med. Jürgen Braun joins the Scientific Advisory Board of MetrioPharm AG. · With more than 800 peer-reviewed publications and various prestigious awards, Prof. Braun is internationally recognized as a leading expert in the field of modern clinical and academic rheumatology.
Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning
The upgraded platform offers a searchable database of over 300 risk-assessed HCPs, automated research scanning, and new flexible pricing options for mid-size drug developers.
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging